Format

Send to

Choose Destination
Pharmacogenomics J. 2019 Feb 11. doi: 10.1038/s41397-019-0076-2. [Epub ahead of print]

Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.

Author information

1
Center for Personalized Therapeutics, The University of Chicago, Chicago, IL, USA.
2
Department of Health Sciences, The University of Chicago, Chicago, IL, USA.
3
Center for Research Informatics, The University of Chicago, Chicago, IL, USA.
4
Department of Medicine, The University of Chicago, Chicago, IL, USA.
5
MacLean Center for Clinical Medical Ethics, The University of Chicago, Chicago, IL, USA.
6
Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL, USA.
7
University of Colorado/Denver Health, Denver, CO, USA.
8
Northwestern University, Chicago, IL, USA.
9
The Center for Health and the Social Sciences, The University of Chicago, Chicago, IL, USA.
10
Center for Personalized Therapeutics, The University of Chicago, Chicago, IL, USA. podonnel@medicine.bsd.uchicago.edu.
11
Department of Medicine, The University of Chicago, Chicago, IL, USA. podonnel@medicine.bsd.uchicago.edu.
12
Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL, USA. podonnel@medicine.bsd.uchicago.edu.

Abstract

Effective doctor-patient communication is critical for disease management, especially when considering genetic information. We studied patient-provider communications after implementing a point-of-care pharmacogenomic results delivery system to understand whether pharmacogenomic results are discussed and whether medication recall is impacted. Outpatients undergoing preemptive pharmacogenomic testing (cases), non-genotyped controls, and study providers were surveyed from October 2012-May 2017. Patient responses were compared between visits where pharmacogenomic results guided prescribing versus visits where pharmacogenomics did not guide prescribing. Provider knowledge of pharmacogenomics, before and during study participation, was also analyzed. Both providers and case patients frequently reported discussions of genetic results after visits where pharmacogenomic information guided prescribing. Importantly, medication changes from visits where pharmacogenomics influenced prescribing were more often recalled than non-pharmacogenomic guided medication changes (OR = 3.3 [1.6-6.7], p = 0.001). Case patients who had separate visits where pharmacogenomics did and did not, respectively, influence prescribing more often remembered medication changes from visits where genomic-based guidance was used (OR = 3.4 [1.2-9.3], p = 0.02). Providers also displayed dramatic increases in personal genomic understanding through program participation (94% felt at least somewhat informed about pharmacogenomics post-participation, compared to 61% at baseline, p = 0.04). Using genomic information during prescribing increases patient-provider communications, patient medication recall, and provider understanding of genomics, important ancillary benefits to clinical use of pharmacogenomics.

PMID:
30713337
DOI:
10.1038/s41397-019-0076-2

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center